No Data
SH PHARMA (601607.SH): Ursodeoxycholic acid capsules have been approved for production.
On January 22, Gelonghui reported that SH PHARMA (601607.SH) announced that its holding subsidiary, Changzhou Pharmaceutical Factory Co., Ltd. (referred to as "Changzhou Pharmaceutical Factory"), has received the "Pharmaceutical Registration Certificate" (Certificate No: 2025S00209) issued by the National Medical Products Administration for ursodeoxycholic acid capsules (specification: 250mg; referred to as "the pharmaceutical"). This pharmaceutical has been approved for production. Ursodeoxycholic acid capsules are primarily used to treat cholesterol gallstones in the gallbladder—specifically, stones that are penetrable by X-rays, and the gallbladder must have normal contraction function; cholestatic liver disease (e.g., primary biliary cirrhosis); and bile reflux gastritis.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.
Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.
China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.
In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
